Shujun Cheng 

Ph.D 

Academician

Chinese Society of Engineering

Professor Shujun Cheng, born in Lin’an, Zhejiang Province, is a CPC member and researcher. He graduated from the Department of Medicine in Beijing Medical College in 1962; in 1965 he graduated as an Experimental Oncology Major from the Department of Pathology in PUMC; from Sept. 1978 to Feb. 1981, he went to INCa for further study on Genetic Toxicology; from Sept. 1986 to Jul. 1987, he served as visiting scholar in Medical College of Ohio; in 1992 and 1996, he served as visiting professor respectively in NKI and MD Anderson Cancer Center. He used to serve as Deputy Head and President of CAMS Cancer Institute and Hospital (from 1992 to 2001), Chairman of CEMS (from 2003 to 2012), Vice Chairman of Chinese Anti-cancer Association (from 2004 to 2012), Chief Scientist of “973” Cancer Project of National Key Fundamental Research Development Program (from 1999 to 2009), Chief Scientist of Beijing Major Cancer Program (from 2005 to 2010) and Chief Scientist of Oncology of the Ministry of Health (from 2009 to 2013). He’s now the Editor-in-chief of Carcinogenesis, Teratogenesis & Mutagenesis.

Engaged in researches of oncology for more than 50 years,Professor  Shujun Cheng found that green tea and its chief ingredient catechin have anti-cancer effect during his researches of anticarcinogens, and that catechin features evident therapeutic effect as to condylomata acuminate and inflammation hyperplasia. The treatment of condylomata acuminate by catechin has been awarded an international patent, and the drug developed based on this has been released to market with the approval of FDA in 2006. It’s the first time that a botanical drug of complex ingredients was approved to be sold in the market as a prescription drug for more than 50 years in the US, thus having significant social and economic benefits and int’l influence. Researcher Shujun Cheng led his team to build up serum-free epithelial cell culturing technique to first establish four immortalized epithelial cell lines of Chinese and build up the model of precancerous lesions of human lung cancer, thus proposing that revealing the mechanism of the occurrence and reversion of precancerous lesions should be made the major direction of cancer prevention and treatment in China today, which was listed among the first projects of “National Key Fundamental Research”. He also took the post of Principal Investigator of “Fundamental Research of the Formation and Development of Malignant Tumor”.

Professor Cheng has won Science and Technology Achievement Award of the Ministry of Health for many times and other state-level honors. In 1990, he was awarded the title “Outstanding Returned Overseas Scholar of National Health Institutions” by the Ministry of Health; in 1991, he was granted the honor “Returned Overseas Scholar of Outstanding Contributions” by State Education Commission and the Ministry of Personnel; in 1994, he won the honor of “Middle-aged and Young Expert of Significant Contributions” from the Ministry of Health; in 2009, he won Ho Leung Ho Lee Foundation Award for Medicine and Pharmacy. He was admitted into the Chinese Academy of Engineering in 1999.